Queen's-based clinical trials group spearheads leading-edge cancer research
A new $12.6 million High Impact Clinical Trials (HICT) program announced today at Queen’s by The Ontario Institute for Cancer Research (OICR) will help advance cancer treatments for patients, including those with rare forms of the disease.
“The HICT Program has been designed to evaluate innovative technologies that will lead to more personalized, targeted medicines that are more effective and less toxic. It will ensure the best research discoveries are developed into new approaches for treating cancer patients,” says Dr. Janet Dancey, HICT Program Director, Professor of Oncology at Queen’s University, and Director of Clinical Translational Research at the Queen’s-based NCIC Clinical Trials Group (NCIC-CTG).
A major focus of the new program is the Rare Tumor Clinical Trials Initiative, which brings together a multidisciplinary team of clinical investigators, pathologists and genomics researchers to investigate new solutions to treating rare tumors. The initiative is a partnership of OICR, Pfizer Canada, and NCIC CTG, a national academic clinical trials cooperative group based at Queen’s.
“This funding from the Ontario Institute for Cancer Research reflects Queen’s significant engagement in leading-edge cancer research, partnership initiatives, and multidisciplinary learning,” says Vice-Principal (Research) Steven Liss. “Queen’s is a world-class research-intensive university and I am delighted that this investment in the NCIC Clinical Trials Group will help advance understanding of these rare types of cancer.”
For more information about the HICT Program, please visit the OICR website.